Learn how analytical methodologies can be used to identify RSV pre- and post-fusion proteins for vaccine development.

It marks another quarter of growing pains for the company, which is racing to launch new products and recover from the decline of its Covid business.

Reports fourth quarter revenues of $1.0 billion, GAAP net loss of $(1.1) billion and GAAP EPS of $(2.91); loss includes approximately $0.2 billion of non-cash charges related to manufacturing resizing ...